share_log

中基長壽科學：根據一般授權認購新股份

ZHONG JI LS: SUBSCRIPTION OF NEW SHARES UNDER GENERAL MANDATE

HKEX ·  May 30 19:34
Summary by Futu AI
中基長壽科學集團有限公司於2024年5月30日交易時段後，與三位認購人簽訂認購協議，條件性同意發行及配發合共91,088,258股新股份，每股定價0.215港元。此次認購將擴大公司已發行股本約16.67%，籌得總額約19,584,000港元，扣除相關開支後淨額約19,384,000港元。淨所得款項60%將用於擴張長壽科學業務及新生物醫藥產品貿易業務，其餘40%將用於一般營運資金。認購價格較最後五個交易日平均收市價折讓約5.62%，而較認購協議當日收市價溢價約0.47%。認購完成須待滿足特定條件，包括獲得聯交所上市委員會批准認購股份上市及買賣等。若條件未能滿足，認購事項將終止。公司股東及潛在投資者應審慎行事。
中基長壽科學集團有限公司於2024年5月30日交易時段後，與三位認購人簽訂認購協議，條件性同意發行及配發合共91,088,258股新股份，每股定價0.215港元。此次認購將擴大公司已發行股本約16.67%，籌得總額約19,584,000港元，扣除相關開支後淨額約19,384,000港元。淨所得款項60%將用於擴張長壽科學業務及新生物醫藥產品貿易業務，其餘40%將用於一般營運資金。認購價格較最後五個交易日平均收市價折讓約5.62%，而較認購協議當日收市價溢價約0.47%。認購完成須待滿足特定條件，包括獲得聯交所上市委員會批准認購股份上市及買賣等。若條件未能滿足，認購事項將終止。公司股東及潛在投資者應審慎行事。
After the trading period of 30 May 2024, China Key Longevity Sciences Group Limited has entered into subscription agreements with three subscribers, conditionally agreeing to issue and issue a total of 91,088,258 new shares priced at HK$0.215 per share. The acquisition will expand the Company's issued share capital by approximately 16.67% to raise a total of approximately HK$19,584,000, net of related expenses of approximately HK$19,384,000. 60% OF THE NET PROCEEDS WILL BE USED TO EXPAND THE LONGEVITY SCIENCE BUSINESS AND NEW BIOMEDICAL PRODUCT TRADING BUSINESS, WHILE THE REMAINING 40% WILL BE USED FOR GENERAL WORKING CAPITAL. The subscription price was approximately 5.62% off the average closing price over the last five trading days, and a premium of 0.47% over the closing price on the day of the subscription agreement. Subscription completion is subject to certain conditions, including approval by the Listing Committee of the Exchange of Exchange for the subscription and sale of shares. If the conditions are not met, the subscription will be terminated. Shareholders and potential investors should act with caution.
After the trading period of 30 May 2024, China Key Longevity Sciences Group Limited has entered into subscription agreements with three subscribers, conditionally agreeing to issue and issue a total of 91,088,258 new shares priced at HK$0.215 per share. The acquisition will expand the Company's issued share capital by approximately 16.67% to raise a total of approximately HK$19,584,000, net of related expenses of approximately HK$19,384,000. 60% OF THE NET PROCEEDS WILL BE USED TO EXPAND THE LONGEVITY SCIENCE BUSINESS AND NEW BIOMEDICAL PRODUCT TRADING BUSINESS, WHILE THE REMAINING 40% WILL BE USED FOR GENERAL WORKING CAPITAL. The subscription price was approximately 5.62% off the average closing price over the last five trading days, and a premium of 0.47% over the closing price on the day of the subscription agreement. Subscription completion is subject to certain conditions, including approval by the Listing Committee of the Exchange of Exchange for the subscription and sale of shares. If the conditions are not met, the subscription will be terminated. Shareholders and potential investors should act with caution.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.